Semax

Overview

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, developed in Russia as a non-hormonal neuroactive peptide. It pairs the neuroactive ACTH(4-7) core (Met-Glu-His-Phe) with a C-terminal Pro-Gly-Pro that slows enzymatic degradation, giving a markedly longer in-vivo window than the native fragment while stripping the corticotropic activity of full-length ACTH. It is studied for nootropic, neuroprotective, and BDNF-modulating effects in cognitive and cerebrovascular research models. For the offered or supplied lot, Vialdyne documents Semax acetate is released at ≥99.0% HPLC main-peak purity, with a batch COA bundling RP-HPLC peak integration, peptide-content assay, water (Karl Fischer), acetic-acid counter-ion, residual solvents, and endotoxin. LC-MS/MS sequence confirmation and the raw chromatogram are available as documented add-ons on the same lot for labs qualifying a new reference source.

Applications & buyer fit

Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

80714-61-0

Molecular Formula

C37H51N9O10S

Molecular Weight

813.93 g/mol

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 2-5 minutes

MOQ

On request

Lead time

7–14 days

Storage

-20°C, protect from light

Certificate of Analysis

Representative COA previews for Semax; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Semax

VD260428-SX10182 · 99.09%

VerifiedRequest full COA →

Semax

VD260428-SX5181 · 98.91%

Regulatory note

Research-use-only reference material. Semax is registered as a medicine in the Russian Federation but is not approved by the FDA or EMA; not for human or veterinary use. Buyers are responsible for verifying regulatory status in the destination market.

Selected literature

1. Dolotov OV, Karpenko EA, Seredenina TS, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(1):82-86.
2. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500.
3. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79.
4. Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel Insights into the Protective Properties of ACTH(4-7)PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats. Genes (Basel). 2020;11(6):681.
5. Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68(5):1144-1146.
6. Radchenko AI, Kuzubova EV, Apostol AA, et al. The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease. Acta Naturae. 2025;17(4):110-120.

Frequently asked questions